These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 9494596

  • 1. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S, Schröder W, Steinhagen G, Koch R, Veuskens U, Schmitz FJ, Handt S, Böcking A.
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [Abstract] [Full Text] [Related]

  • 2. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP, Hoop JG, van Beers M, van Rodijnen N, Pannebakker M, Nap M.
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [Abstract] [Full Text] [Related]

  • 3. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B, International Breast Cancer Study Group.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1571-81. PubMed ID: 17077359
    [Abstract] [Full Text] [Related]

  • 4. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
    Biesterfeld S, Veuskens U, Schmitz FJ, Amo-Takyi B, Böcking A.
    Anticancer Res; 1996 Nov 01; 16(5A):2497-500. PubMed ID: 8917341
    [Abstract] [Full Text] [Related]

  • 5. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, Hendrickx W, Decock J, Huang HJ, Leunen K, Amant F, Berteloot P, Paridaens R, Wildiers H, Van Limbergen E, Weltens C, Timmerman D, Van Gorp T, Smeets A, Van den Bogaert W, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 Jan 01; 113(1):181-7. PubMed ID: 18264760
    [Abstract] [Full Text] [Related]

  • 6. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 Jan 01; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 7. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
    Biesterfeld S, Klüppel D, Koch R, Schneider S, Steinhagen G, Mihalcea AM, Schröder W.
    J Pathol; 1998 May 01; 185(1):25-31. PubMed ID: 9713356
    [Abstract] [Full Text] [Related]

  • 8. [Cancer of the breast and the receptor status].
    Buonomo O, Serao A, Muggianu A, Guglielmelli E, Davoli E, Amori A.
    G Chir; 1991 Apr 01; 12(4):274-7. PubMed ID: 1911078
    [Abstract] [Full Text] [Related]

  • 9. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
    Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K.
    Anticancer Res; 1991 Apr 01; 11(5):1701-6. PubMed ID: 1768039
    [Abstract] [Full Text] [Related]

  • 10. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma.
    Gehrig PA, Van Le L, Olatidoye B, Geradts J.
    Cancer; 1999 Nov 15; 86(10):2083-9. PubMed ID: 10570435
    [Abstract] [Full Text] [Related]

  • 11. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
    Skasko E, Paszko Z, Mazur S.
    Neoplasma; 2005 Nov 15; 52(1):10-7. PubMed ID: 15739020
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC).
    Beck T, Weikel W, Brumm C, Wilkens C, Pollow K, Knapstein PG.
    Gynecol Oncol; 1994 May 15; 53(2):220-7. PubMed ID: 8188083
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of intra-tumoral estradiol level in breast cancer patients.
    Miyoshi Y, Akazawa K, Kamigaki S, Ueda S, Yanagisawa T, Inoue T, Yamamura J, Taguchi T, Tamaki Y, Noguchi S.
    Cancer Lett; 2004 Dec 08; 216(1):115-21. PubMed ID: 15500955
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 15. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G.
    J Clin Oncol; 2008 Aug 01; 26(22):3727-34. PubMed ID: 18669459
    [Abstract] [Full Text] [Related]

  • 16. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 May 01; 115(2):349-58. PubMed ID: 18629635
    [Abstract] [Full Text] [Related]

  • 17. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
    Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, Shen ZZ, Shao ZM, Wu J.
    Oncol Rep; 2008 Oct 01; 20(4):987-94. PubMed ID: 18813844
    [Abstract] [Full Text] [Related]

  • 18. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J, Holubec L, Topolcan O, Elgrova L, Skalova A, Pecen L.
    Anticancer Res; 2007 Oct 01; 27(4A):1893-6. PubMed ID: 17649790
    [Abstract] [Full Text] [Related]

  • 19. Progesterone and estrogen receptors as prognostic variables in breast cancer.
    Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG.
    Cancer Res; 1983 Jun 01; 43(6):2985-90. PubMed ID: 6850609
    [Abstract] [Full Text] [Related]

  • 20. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
    Aftimos G, Trak-Smayra V, Moacdieh-Rehayel L.
    J Med Liban; 2000 Jun 01; 48(1):8-17. PubMed ID: 10881437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.